Lin Xichen 4

4 · Structure Therapeutics Inc. · Filed Mar 23, 2026

AI-generated summary of this filing

Updated Mar 23, 2026

Structure Therapeutics (GPCR) CSO Lin Xichen Receives Stock Awards

What Happened

Lin Xichen, Chief Scientific Officer of Structure Therapeutics (GPCR), received equity awards on March 19, 2026: 43,368 ordinary shares and 53,703 derivative awards (RSUs), for a total of 97,071 shares granted at $0.00 per share. These were reported on a Form 4 filed March 23, 2026. The awards were grants (code A) — not open‑market purchases or sales.

Key Details

Transaction date: 2026-03-19; Form 4 filed: 2026-03-23 (filed timely).
Grant amounts and price: 43,368 shares @ $0.00 (acquired) and 53,703 derivative shares @ $0.00 (acquired); combined = 97,071 shares.
ADS conversion: 1 ADS = 3 ordinary shares (footnote); 97,071 ordinary shares ≈ 32,357 ADSs.
Vesting/terms: Footnote F2 states the RSUs vest 1/4 annually on each anniversary of March 1, 2026, subject to continued service. Footnotes F3 and F4 describe standard option pricing/vesting language but no option exercise was reported in this filing.
Shares owned after the transaction were not specified in the provided excerpt of the filing.
No 10b5‑1 plan, tax‑withholding sale, or late‑filing indication was disclosed in the provided notes.

Context

These grants are awards (compensation), not purchases — they reflect compensation/retention incentives rather than an immediate market buy or sell signal. The RSUs are contingent and vest over time, so economic ownership and transferability may be limited until vesting conditions are met.

Form 4

Period: 2026-03-19

CHIEF SCIENTIFIC OFFICER

Transactions

Award
Ordinary Shares
[F1][F2]
2026-03-19+43,368→ 228,960 total
Award
Employee Stock Option (right to buy)
[F3][F4][F1]
2026-03-19+53,703→ 53,703 total
Exercise: $16.82Exp: 2036-03-18→ Ordinary Shares (53,703 underlying)

Footnotes (4)

[F1]The Ordinary Shares of the Issuer may be represented by American Depositary Shares ('ADSs"). Each ADS represents three Ordinary Shares of the Issuer.
[F2]Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one ordinary share of the Issuer. The RSUs vest 1/4th annually on each anniversary of March 1, 2026, subject to Reporting Person's continued service on such dates.
[F3]The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's ADSs.
[F4]1/4th of the shares subject to the option shall vest March 1, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date.

Signature

/s/ Jun Yoon, Attorney-in-Fact|2026-03-22

1 file